SecurityBridge Acquires CyberSafe To Deliver Contextual SSO, MFA, And Passwordless Authentication To SAP Users
23.7.2025 13:00:00 CEST | Business Wire | Press release
SecurityBridge, the creator of the Cybersecurity Command Center for SAP, today announced the acquisition of CyberSafe, a UK-based pioneer in multi-factor authentication (MFA) and single sign-on (SSO) solutions for SAP users. The acquisition marks a significant milestone in SAP security innovation, as CyberSafe’s flagship TrustBroker® products will further enrich the SecurityBridge platform capabilities. A two-way integration enables customers to transition from password-based authentication to multi-factor authentication across the SAP technology stack, with full insight into the SAP application layer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250723384838/en/

SecurityBridge, the leading SAP security software provider, acquires MFA and SSO software company CyberSafe.
“SAP’s native security lacks the depth today’s threat landscape demands,” said Christoph Nagy, CEO and Co-founder of SecurityBridge. “This acquisition reinforces our mission to ensure no SAP system or customer is ever compromised. By integrating TrustBroker with our platform, we enable customers to apply passwordless MFA across all SAP workflows, without compromising usability. However, customers can still use TrustBroker products standalone.”
With a glowing global customer base spanning all industry segments and over three decades of cybersecurity expertise, CyberSafe brings deep authentication capabilities and a proven track record in enterprise-class identity protection. The TrustBroker products offer secure single sign-on (SSO), policy-based MFA during login, and step-up authentication (SUA), utilizing leading MFA applications, such as Microsoft Entra MFA (formerly Azure MFA), Okta, PingID, Duo, RSA SecurID, and TOTP/HOTP apps. Once integrated with SecurityBridge, TrustBroker products will act upon real-time threat signals, such as anomalous logon behavior, suspicious devices, and past user activity, to determine when MFA enforcement is necessary, thereby adding contextual intelligence to SAP user authentication.
“For over three decades, CyberSafe has been at the forefront of integrating SAP user authentication with existing infrastructure, such as Microsoft Active Directory,” said Tim Alsop, Managing Director of CyberSafe. “Joining forces with SecurityBridge facilitates building new products and enhancing existing products while leveraging the growing adoption of modern authentication methods. I am also looking forward to being able to deliver integration with the SecurityBridge platform, so that our TrustBroker products can offer contextual and risk-based MFA.”
The combined platform offering behavior-based enforcement policies with MFA takes SAP security to a new level by:
- Automatically enforcing MFA when users return after long periods of inactivity (e.g., 90+ days).
- Prompting MFA for logins outside of a user’s standard working hours.
- Enforcing MFA when logins originate from devices not previously associated with the user.
- Requiring additional authentication for users with past suspicious behavior or flagged activity.
- Triggering MFA when access occurs from devices used by multiple individuals.
These context-aware measures will seamlessly adapt authentication requirements to each situation, reducing user friction during normal activity while strengthening protection against abnormal or high-risk access attempts.
About CyberSafe
CyberSafe is a leading global security software vendor, providing mature, proven, standards-based solutions that enable true enterprise-class single sign-on (SSO), policy-based multi-factor authentication (MFA), and step-up authentication (SUA) for mission-critical SAP business applications. In 1991, the company pioneered the first commercial Kerberos-based security product, including being the first to provide critical security interoperability between Microsoft Windows and non-Microsoft operating systems and applications. More recently, CyberSafe has pioneered step-up authentication for SAP users, a feature not available from any other software vendor. The TrustBroker products are flexible and leverage existing infrastructure to minimize implementation and ongoing costs.
About SecurityBridge
SecurityBridge is the leading provider of a comprehensive, SAP-native cybersecurity platform, enabling organizations worldwide to protect their most critical business systems. The platform seamlessly integrates real-time threat monitoring, vulnerability management, and compliance capabilities directly into the SAP environment, enabling organizations to protect their data's integrity, confidentiality, and availability with minimal manual effort. It provides a 360° view of the SAP security situation and is characterized by user-friendliness, rapid implementation, and transparent licensing. SecurityBridge has a proven track record, including an excellent customer rating and over 7,500 secured SAP systems worldwide. The company is committed to innovation, transparency, and customer focus, ensuring that SAP users can confidently navigate the evolving landscape of SAP security threats. For more information, please visit www.securitybridge.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250723384838/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom